AR-SA">B-cell depletion and recovery after treatment with the anti-CD20 monoclonal antibody rituximab in patients with posttransplant lymphoproliferative disorders (PT-LPD).

被引：0
|
作者：
Grefer, J
Oertel, SH
Hummel, M
Serke, S
Reinke, P
Jonas, S
Anagnostopoulos, I
Arnold, R
Dörken, B
Riess, H
机构：
[1] Humboldt Univ, Klinikum Rudolf Virchow, Charite, Berlin, Germany
[2] Deutsches Herzzentrum, Berlin, Germany
[3] Free Univ Berlin, D-1000 Berlin, Germany
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4693
引用
收藏
页码：242B / 242B
页数：1
相关论文
共 50 条
  • [41] Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
    Czuczman, MS
    Grillo-López, AJ
    White, CA
    Saleh, M
    Gordon, L
    LoBuglio, AF
    Jonas, C
    Klippenstein, D
    Dallaire, B
    Varns, C
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 268 - 276
  • [42] Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children
    Faye, A
    Quartier, P
    Reguerre, Y
    Lutz, P
    Carret, AS
    Dehée, A
    Rohrlich, P
    Peuchmaur, M
    Matthieu-Boué, A
    Fischer, A
    Vilmer, E
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (01) : 112 - 118
  • [43] Complement activation in circulation and central nervous system after Rituximab (Anti-CD20) treatment of B-Cell lymphoma
    Harjunpää, A
    Wiklund, T
    Collan, J
    Janes, R
    Rosenberg, J
    Lee, D
    Grillo-López, A
    Meri, S
    LEUKEMIA & LYMPHOMA, 2001, 42 (04) : 731 - 738
  • [44] Treatment of B cell low grade non-Hodgkin's lymphoma (NHL) with anti-CD20 monoclonal antibody Rituximab®
    Federico, M
    Clo, V
    Vinci, G
    Sacchi, S
    ANNALS OF ONCOLOGY, 1998, 9 : 32 - 32
  • [45] Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation
    Beers, Stephen A.
    Chan, Claude H. T.
    James, Sonya
    French, Ruth R.
    Attfield, Kathrine E.
    Brennan, Claire M.
    Ahuja, Anupama
    Shlomchik, Mark J.
    Cragg, Mark S.
    Glennie, Martin J.
    BLOOD, 2008, 112 (10) : 4170 - 4177
  • [46] Effect of Subcutaneous Treatment With Anti-CD20 Antibody on B-cell Depletion in a Lipopolysaccharide-Induced Inflammatory Mouse Model
    Dawson, Janet
    Touil, Ismahane
    Scheidegger, Anja
    Vogelsanger, Melanie
    Leppert, David
    Weckbecker, Gisbert
    NEUROLOGY, 2019, 92 (15)
  • [47] Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas - an applicational observation
    Gellrich, S
    Muche, JM
    Wilks, A
    Jasch, KC
    Voit, C
    Fischer, T
    Audring, H
    Sterry, W
    BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (01) : 167 - 173
  • [48] A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
    Tobinai, Kensei
    Klein, Christian
    Oya, Naoko
    Fingerle-Rowson, Gunter
    ADVANCES IN THERAPY, 2017, 34 (02) : 324 - 356
  • [49] A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
    Kensei Tobinai
    Christian Klein
    Naoko Oya
    Günter Fingerle-Rowson
    Advances in Therapy, 2017, 34 : 324 - 356
  • [50] Citrobacter koseri Cellulitis During Anti-CD20 Monoclonal Antibody (Ofatumumab) Treatment for B-cell Chronic Lymphocytic Leukaemia
    Kluger, Nicolas
    Cartron, Guillaume
    Bessis, Didier
    Guillot, Bernard
    Girard, Celine
    ACTA DERMATO-VENEREOLOGICA, 2010, 90 (01) : 99 - 100
12345